TRPH-222, an antibody–drug conjugate targeting CD22, resulted in limited activity in DLBCL in a phase I trial that included 10 patients with DLBCL/transformed FL with an ORR of 20% [58]. The gene discussed is TPH1; the disease is diffuse large B-cell lymphoma.